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Xiaoli Sun1, Wu Sui2, Miaoling Huang3, Yeli Wang3, Yuanjie Xuan3 and Zaiqiu Wang3*Abstract
Background: Partner of Sld five 3 (PSF3) is a member of the evolutionarily conserved heterotetrameric complex
“Go-Ichi-Ni-San” (GINS), which consists of SLD5, PSF1, PSF2, and PSF3. Previous studies have suggested that some
GINS complex members are upregulated in cancer, but the status of PSF3 expression in colorectal cancer has not
been investigated.
Methods: We investigated the status of PSF3 expression in 137 consecutive resected colorectal caners by
quantitative reverse-transcription polymerase chain reaction. Univariable and multivariable Cox regression analyses
were performed to assess independent prognostic factors for overall survival in colorectal cancer.
Results: In 137 restected colorectal cancer samples, median messenger RNA (mRNA) expression levels of PSF3 were
significantly higher in tumor tissues (1.35 × 10−3, range 2.88 × 10−4 to 3.16 × 10−2) than in adjacent normal tissues
(2.94 × 10−4, range 5.48 × 10−5 to 1.27 × 10−3) (P < 0.05). Moreover, high expression of PSF3 in tumor tissues was
associated with shorter disease-free survival and overall survival. When analyzed with a Cox regression model, the
PSF3 expression was an independent prognostic factor for overall survival. In addition, in patients with early stage
(stage I and II) colorectal cancer, the overall survival rate of the high PSF3 expression group was significantly lower
than that of the low PSF3 expression group (P < 0.001).
Conclusions: The PSF3 expression plays an important role in the progression of colorectal cancer and acts as a
factor significantly affecting the prognosis of patients.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_217
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Partner of Sld five 3 (PSF3) is a member of the highly
evolutionarily conserved tetrameric complex termed Go-
Ichi-Ni-San (GINS), composed of SLD5, PSF1, PSF2,
and PSF3. In yeast, the GINS complex associates with
the Minichromosome maintenance (MCM) 2–7 complex
and CDC45, and this “CMG complex” (CDC45/MCM2-
7/GINS) regulates both the initiation and progression of
DNA replication [1-3]. Thus, it has been suggested that
GINS is involved in DNA replication in Xenopus and
human [4-6]. However, a recent study suggested that
PSF1/PSF2 is associated with the response to replication* Correspondence: zaiqiu_wang@yeah.net
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unless otherwise stated.stress and acquisition of DNA damage in untransformed
human dermal fibroblasts [7]. As it has been reported
that DNA replication-associated protein in yeast has di-
verse functions in different cells, e.g. origin recognition
protein Orc1 has a role in determining centrosome copy
number [8], the exact functions of GINS components in
mammalian cells are not yet clear.
Several recent reports have suggested that PSF1 is re-
quired for the acute proliferation of cells, particularly
immature cells such as stem cells and progenitor cells
and that this protein is useful in the successful detection
of cancer stem cells [9-12]. Moreover, previous studies
have suggested that some GINS complex members are
upregulated in cancer, and some GINS components may
be useful in the detection of cancer stem cells [13,14].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ponents play a role in cancer [15,16], the expression status
of these components in patients with colorectal cancer has
not yet been examined. Therefore, we sought to evaluate
the mRNA expression status of PSF3 in surgically resected
samples of colorectal cancer tissue. We also investigated
whether PSF3 expression in tumor tissues influenced the
prognosis of these patients.
Methods
Patients
The study population comprised 137 consecutive pa-
tients (79 males and 58 females) who were examined
and treated at Yuhuangding Hospital between January
2008 and December 2012 for colorectal cancer. All cases
underwent complete resection in this study. Details
of the clinical and demographic information, prognosticTable 1 Association between mRNA expression of PSF3 and c
colorectal cancer
Variables Total
No. of patients 137

























M/F Male/Female, PSF3 partner of Sld five 3, SD standard deviation.
*Significant P-value.factors, and disease progression were collected prospect-
ively. Of the 137 patients, 46, 54, 22, and 15 had stage I,
II, III, and IV tumors, respectively. Forty-two patients
were administered postoperiative adjuvant chemotherapy
every three weeks for six months (Oxaliplatin 130 mg/
m2 d1 + Capecitabine 1000 mg/m2 d1-d14). The study
protocol was approved by the institutional review board
of Yuhuangding Hospital and the study was conducted
according to the principles of the Declaration of Helsinki.
All patients provided written informed consent.
RNA isolation and qRT-PCR
Quantitative reverse-transcription polymerase chain reac-
tion (qRT-PCR) was used to determine the PSF3 expres-
sion level. Briefly, total RNA was extracted with Trizol
reagent (Invitrogen, Grand Island, NY, USA) and dissolved
in water according to the manufacturer’s instructions.linicopathological characteristics in 137 patients with
PSF3 expression P-value
Low level High level
66 71

























Figure 1 Kaplan-Meier estimates of disease-free survival (A)
and overall survival (B) for all patients and overall survival for
early stage colorectal cancer patients (C).
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PSF3 and an internal reference gene (β-actin) was done
using a fluorescence-based, real-time detection method.
The sequences of the primer used were as follows: PSF3
forward 5′-TGACAGTCCCGAGAATGCAGA-3′ and re-
verse 5′-TGCCTACCAGGGCTGAAGTG-3′; β-actin (in-
ternal reference gene) forward 5′-TGGCACCCAGCAC
AATGAA-3′, reverse 5′-CTAAGTCATAGTCCGCCTA
GAAGCA-3′. The PCR mixture consisted 1200 nmol/l
primer, 200 nmol/l probe, 200 nmol/l each of deoxyade-
nosine triphosphate, deoxycytidine triphosphate, deoxy-
guanosine triphosphate, deoxythymidine triphosphate,
3.5 mmol/l MgCl2, and × 1 Taqman Universal PCR Master
mix to a final volume of 20 μl (all reagents were from
PE Applied Biosystems, Foster City, CA). Cycling condi-
tions were 95°C for 35 s and 60°C for 30s, followed by
40 cycles at 95°C for 15 s and 60°C for 1 min. Relative
gene expression levels are expressed as ratios (differ-
ences between the Ct values) between two absolute
measurements (PSF3/β-actin).
Follow-up
The follow-up period was defined as the interval be-
tween the date of operation and the date of the patient’s
death or the last visit. The follow-up time ranged from
7 months to 73 months (median, 41 months). All pa-
tients were followed until May 2014 with a follow-up
rate of 100%. Disease-free survival was measured from
the day of surgery to the day of the first evidence of
tumor recurrence or metastasis. Overall survival was
measured from the day of surgery to the day of death.
Statistical analysis
Associations between PSF3 expression in tumor tissue
and clinicopathological features were determined using the
χ2-test. Survival was examined using the Kaplan-Meier
method, and the significance of the difference was evaluated
by a log-rank test. A Cox regression analysis was carried
out to assess independent prognostic factors for disease-
free survival and overall survival in colorectal cancer. All
statistical calculations were performed using SPSS software
(SPSS 17.0, Chicago, IL, USA) and P <0.05 was considered
statistically significant.
Results
PSF3 expression level in colorectal cancer
The mRNA expression level of PSF3 were determined in
137 colorectal cancer and the adjacent normal tissues by
qRT-PCR. Median mRNA expression levels were 1.35 ×
10−3 (range 2.88 × 10−4 to 3.16 × 10−2) for tumor tissues
and 2.94 × 10−4 (range 5.48 × 10−5 to 1.27 × 10−3) for
adjacent normal tissues, and the differences were statisti-
cally significant (P < 0.05). To evaluate the role of PSF3
in colorectal cancer, we investigated whether PSF3 expressionwas associated with any of clinicopathological variables in
the 137 enrolled cases of colorectal cancer. By adopting
cut-off value according to median PSF3 expression level,
we found that PSF3 expression was significantly associated
with tumor size, depth of wall invasion, lymph node me-
tastasis, TNM stage, tumor differentiation, and five-year
survival. No significant relationship was noted between
PSF3 expression and age, gender, distant metastasis, and
adjuvant chemotherapy (Table 1).
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prognosis
Using the data collected from 137 patients, we evaluated
their prognosis and its relationship to the expression of
PSF3. The disease-free survival in patients with low PSF3
levels (39.5 ± 7.2 months) was significantly longer than that
in patients with high levels (28.6 ± 6.4 months) (P = 0.007;
Figure 1A). Univariate analysis initially included age, gen-
der, tumor size, depth of wall invasion, lymph node metas-
tasis, distant metastasis, tumor differentiation, TNM stage,
adjuvant chemotherapy, and PSF3 expression level for
disease-free survival analysis. The tumor size, lymph node
metastasis, distant metastasis, TNM stage, tumor differen-
tiation, adjuvant chemotherapy, and PSF3 expression level
were associated with disease-free survival and were intro-
duced into the multivariate analysis (Table 2). In the multi-
variate analysis, late TNM stage, poor differentiation, and
high PSF3 level were shown to have a statistically inde-
pendent prognostic value with respect to disease-free sur-
vival (Table 2). In addition, we also examined the overall
survival of PSF3 low level and PSF3 high level groups
and found a statistically difference between the two
groups by using the log-rank test (P = 0.003). The median
survival time of patients with low PSF3 levels (59.7 ±
13.8 months) was significantly longer than that of patients
with high PSF3 levels (47.2 ± 11.4 months) (Figure 1B). A
univariate analysis indicated that among the clinicopatho-
logical factors, tumor size, lymph node metastasis, distant
metastasis, tumor differentiation, TNM stage, adjuvant
chemotherapy, and PSF3 expression level were correlated
with the outcome (Table 3). Further assessment using the
Cox multivariate analysis indicated that distant metastasis,
poor differentiation, late TNM stage, and high PSF3 ex-
pression were statistically significant predictors for poor






Tumor size 1.32 (1.03-1.58)
Depth of wall invasion 1.14 (0.96-1.35)
Lymph node metastasis 1.74 (1.23-2.28)
Distant metastasis 1.56 (1.19-1.77)
TNM stage 1.91 (1.54-2.60)
Differentiation 1.66 (1.31-2.05)
Adjuvant chemotherapy 1.25 (1.06-1.47)
PSF3 expression 1.83 (1.55-2.17)
CI confidence interval, HR hazard ratio, PSF3 partner of Sld five 3.
*Significant P-value in multivariate analysis.High expression of PSF3 was also associated with poor
patient prognosis in early stage colorectal cancer
In the current study, we further analyzed the association
of PSF3 expression in early stage (stage I and II) colorec-
tal cancer. Among the early stage cases, 46 and 54 pa-
tients were classified as high PSF3 level and low PSF3
level, respectively. A survival analysis that included only
early stage patients revealed that the overall survival
for the low PSF3 expression group was longer than that
for the high PSF3 expression group. The log-rank test
showed that the intergroup difference was statistically
significant (P < 0.001; Figure 1C).
Discussion
PSF3 is a member of the GINS complex, along with Sld5,
PSF1, and PSF2. PSF1 is tightly regulated at the transcrip-
tional level in stem cells and enables the successful detection
of cancer stem cells [9-12]. Therefore, it seems reasonable
that other GINS components may also facilitate the detec-
tion of cancer stem cells in tumors. Cancer stem cells,
which are resistant to anti-cancer drugs and irradiation, ap-
pear to be responsible for tumor growth in hematological
and solid cancers. The detection of these cells is critical for
identifying molecular targets to inhibit their growth. Previ-
ous study has shown that all GINS components are over-
expressed in intrahepatic cholangiocarcinoma tissues and
PSF3 is also increased in lung adenocarcinoma [17]. To
our knowledge, this is the first study to detect PSF3 expres-
sion in colorectal cancer and to show that PSF3 expression
might be a useful prognostic marker for assessing patient
survival in colorectal cancer.
In this study, we performed qRT-PCR of surgically
resected colorectal cancer specimens to determine the
PSF3 status in cancer tissues clinically. The results re-
vealed that PSF3 expression was higher in the colorectaln between the disease-free survival of 137 patients with
Multivariate analysis
P-value HR (95% CI) P-value
0.748
0.396
0.044 1.25 (0.98-1.46) 0.067
0.185
0.006 1.27 (0.94-1.54) 0.083
0.013 1.33 (0.96-1.67) 0.075
<0.001 1.78 (1.21-2.13) 0.008*
0.002 1.45 (1.10-1.78) 0.028*
0.037 1.08 (0.87-1.29) 0.154
<0.001 1.66 (1.36-2.02) 0.003*
Table 3 Univariate and multivariate analyses of the association between the overall survival of 137 patients with
colorectal cancer
Variables Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age 1.12 (0.94-1.31) 0.576
Gender 0.99 (0.87-1.14) 0.834
Tumor size 1.41 (1.13-1.68) 0.033 1.04 (0.89-1.18) 0.473
Depth of wall invasion 1.33 (0.98-1.70) 0.065
Lymph node metastasis 1.47 (1.08-1.85) 0.014 1.24 (0.96-1.47) 0.085
Distant metastasis 1.54 (1.22-1.92) 0.007 1.38 (1.12-1.63) 0.006*
TNM stage 1.67 (1.39-1.94) <0.001 1.48 (1.15-1.77) 0.004*
Differentiation 1.41 (1.18-1.65) 0.009 1.26 (1.02-1.51) 0.041*
Adjuvant chemotherapy 1.37 (1.05-1.74) 0.023 1.14 (0.91-1.39) 0.093
PSF3 expression 1.59 (1.26-1.95) <0.001 1.35 (1.10-1.64) 0.002*
CI confidence interval, HR hazard ratio, PSF3 partner of Sld five 3.
*Significant P-value in multivariate analysis.
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order to elucidate the role of high PSF3 expression on
the prognosis of patients with colorectal cancer, a prog-
nostic analysis was carried using the patients’ follow-up
data. Survival analysis revealed that the disease-free sur-
vival and overall survival in patients with low PSF3 ex-
pression was notably longer than that of patients with
high PSF3 expression. These findings indicated that high
PSF3 expression significantly affected the clinical course
and was correlated with malignant behavior of tumors.
The significance of PSF3 expression on these clinical fea-
tures was also supported by our analysis of the relation-
ship between PSF3 expression and clinicopathological
characteristics of 137 patients. Cox multivariate analysis
indicated that high PSF3 expression was the most signifi-
cant predictor of poor prognosis, rather than the TNM
stage or tumor differentiation. Furthermore, a prognostic
analysis that included only early stage cases (stage I and II)
revealed that the overall survival rate of the high PSF3 ex-
pression group was significantly lower than that of the low
PSF3 expression group. These findings suggest that high
PSF3 expression may be used as a reference index for mo-
lecular staging of patients with a high risk of death and
thereby likely to benefit from intensive adjuvant therapy.
What is the basis of the relationship between high PSF3
expression and poor prognosis? We believe that high PSF3
expression may be related to cancer cell proliferation
because PSF3 was required in the early stage of DNA rep-
lication, along with other GINS members [9-12]. A previ-
ous study by Nagahama et al. found high expression of
PSF3 in several colon carcinoma cell lines (HCT116,
colo320DM, SW837, and HT-29) and that PSF3 gene
knock-down in these cell lines resulted in growth inhib-
ition characterized by delayed S-phase progression [16].The results suggested that PSF3 marks malignant colon
cancer and has a role in cancer cell proliferation.
Conclusions
In conclusion, we have shown that high PSF3 expression
plays an important role in the progression of colorectal
cancer and acts as a factor significantly affecting the prog-
nosis of patients. These results suggested that PSF3 could
be used as a reference index for the molecular staging to
select patients at high risk of death and relapsed patients
who may benefit from intensive adjuvant therapy.
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